Literature DB >> 20526854

Antiproliferative Pt(IV) complexes: synthesis, biological activity, and quantitative structure-activity relationship modeling.

Paola Gramatica1, Ester Papa, Mara Luini, Elena Monti, Marzia B Gariboldi, Mauro Ravera, Elisabetta Gabano, Luca Gaviglio, Domenico Osella.   

Abstract

Several Pt(IV) complexes of the general formula [Pt(L)2(L')2(L'')2] [axial ligands L are Cl-, RCOO-, or OH-; equatorial ligands L' are two am(m)ine or one diamine; and equatorial ligands L'' are Cl- or glycolato] were rationally designed and synthesized in the attempt to develop a predictive quantitative structure-activity relationship (QSAR) model. Numerous theoretical molecular descriptors were used alongside physicochemical data (i.e., reduction peak potential, Ep, and partition coefficient, log Po/w) to obtain a validated QSAR between in vitro cytotoxicity (half maximal inhibitory concentrations, IC50, on A2780 ovarian and HCT116 colon carcinoma cell lines) and some features of Pt(IV) complexes. In the resulting best models, a lipophilic descriptor (log Po/w or the number of secondary sp3 carbon atoms) plus an electronic descriptor (Ep, the number of oxygen atoms, or the topological polar surface area expressed as the N,O polar contribution) is necessary for modeling, supporting the general finding that the biological behavior of Pt(IV) complexes can be rationalized on the basis of their cellular uptake, the Pt(IV)-->Pt(II) reduction, and the structure of the corresponding Pt(II) metabolites. Novel compounds were synthesized on the basis of their predicted cytotoxicity in the preliminary QSAR model, and were experimentally tested. A final QSAR model, based solely on theoretical molecular descriptors to ensure its general applicability, is proposed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20526854     DOI: 10.1007/s00775-010-0676-4

Source DB:  PubMed          Journal:  J Biol Inorg Chem        ISSN: 0949-8257            Impact factor:   3.358


  29 in total

1.  Carboxylation of Kinetically Inert Platinum(IV) Hydroxy Complexes. An Entr.acte.ee into Orally Active Platinum(IV) Antitumor Agents.

Authors:  C M Giandomenico; M J Abrams; B A Murrer; J F Vollano; M I Rheinheimer; S B Wyer; G E Bossard; J D Higgins
Journal:  Inorg Chem       Date:  1995-03       Impact factor: 5.165

2.  The relevance of polar surface area (PSA) in rationalizing biological properties of several cis-diamminemalonatoplatinum(II) derivatives.

Authors:  Giulia Caron; Giuseppe Ermondi; Marzia B Gariboldi; Elena Monti; Elisabetta Gabano; Mauro Ravera; Domenico Osella
Journal:  ChemMedChem       Date:  2009-10       Impact factor: 3.466

Review 3.  The rational design of anticancer platinum complexes: the importance of the structure-activity relationship.

Authors:  Angel M Montaña; Consuelo Batalla
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

4.  Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

Authors:  M C Alley; D A Scudiero; A Monks; M L Hursey; M J Czerwinski; D L Fine; B J Abbott; J G Mayo; R H Shoemaker; M R Boyd
Journal:  Cancer Res       Date:  1988-02-01       Impact factor: 12.701

Review 5.  Determination of hydrophobic parameters by reversed-phase liquid chromatography: theory, experimental techniques, and application in studies on quantitative structure-activity relationships.

Authors:  T Braumann
Journal:  J Chromatogr       Date:  1986-11-14

6.  The influence of tumour microenvironmental factors on the efficacy of cisplatin and novel platinum(IV) complexes.

Authors:  H R Mellor; S Snelling; M D Hall; S Modok; M Jaffar; T W Hambley; R Callaghan
Journal:  Biochem Pharmacol       Date:  2005-10-15       Impact factor: 5.858

7.  New reduction pathways for ctc-[PtCl2(CH3CO2)2(NH3)(Am)] anticancer prodrugs.

Authors:  Alina Nemirovski; Inbal Vinograd; Khuloud Takrouri; Ana Mijovilovich; Annette Rompel; Dan Gibson
Journal:  Chem Commun (Camb)       Date:  2010-02-12       Impact factor: 6.222

8.  Identification of non-cross-resistant platinum compounds with novel cytotoxicity profiles using the NCI anticancer drug screen and clustered image map visualizations.

Authors:  Tito Fojo; Nick Farrell; Waldo Ortuzar; Hideyuki Tanimura; John Weinstein; Timothy G Myers
Journal:  Crit Rev Oncol Hematol       Date:  2005-01       Impact factor: 6.312

9.  The RP-HPLC measurement and QSPR analysis of logP(o/w) values of several Pt(II) complexes.

Authors:  James A Platts; Steven P Oldfield; Maria M Reif; Alessandra Palmucci; Elisabetta Gabano; Domenico Osella
Journal:  J Inorg Biochem       Date:  2006-07       Impact factor: 4.155

10.  Ammine/amine platinum(IV) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cell lines.

Authors:  L R Kelland; B A Murrer; G Abel; C M Giandomenico; P Mistry; K R Harrap
Journal:  Cancer Res       Date:  1992-02-15       Impact factor: 12.701

View more
  18 in total

1.  Molecular and statistical modeling of reduction peak potential and lipophilicity of platinum(IV) complexes.

Authors:  James A Platts; Giuseppe Ermondi; Giulia Caron; Mauro Ravera; Elisabetta Gabano; Luca Gaviglio; Giorgio Pelosi; Domenico Osella
Journal:  J Biol Inorg Chem       Date:  2010-11-16       Impact factor: 3.358

Review 2.  Redox activation of metal-based prodrugs as a strategy for drug delivery.

Authors:  Nora Graf; Stephen J Lippard
Journal:  Adv Drug Deliv Rev       Date:  2012-01-25       Impact factor: 15.470

Review 3.  Synthetic methods for the preparation of platinum anticancer complexes.

Authors:  Justin J Wilson; Stephen J Lippard
Journal:  Chem Rev       Date:  2013-11-27       Impact factor: 60.622

4.  Synthesis, characterization, and cytotoxicity of platinum(IV) carbamate complexes.

Authors:  Justin J Wilson; Stephen J Lippard
Journal:  Inorg Chem       Date:  2011-03-01       Impact factor: 5.165

5.  Elusive Intermediates in the Breakdown Reactivity Patterns of Prodrug Platinum(IV) Complexes.

Authors:  Davide Corinti; Maria Elisa Crestoni; Simonetta Fornarini; Fortuna Ponte; Nino Russo; Emilia Sicilia; Elisabetta Gabano; Domenico Osella
Journal:  J Am Soc Mass Spectrom       Date:  2019-04-12       Impact factor: 3.109

6.  Development of QSAR model for predicting the inclusion constants of organic chemicals with α-cyclodextrin.

Authors:  Mengbi Wei; Xianhai Yang; Peter Watson; Feifei Yang; Huihui Liu
Journal:  Environ Sci Pollut Res Int       Date:  2018-04-17       Impact factor: 4.223

7.  The effect of ligand lipophilicity on the nanoparticle encapsulation of Pt(IV) prodrugs.

Authors:  Timothy C Johnstone; Stephen J Lippard
Journal:  Inorg Chem       Date:  2013-07-16       Impact factor: 5.165

8.  Glutathione-Responsive Prodrug Nanoparticles for Effective Drug Delivery and Cancer Therapy.

Authors:  Xiang Ling; Jiasheng Tu; Junqing Wang; Aram Shajii; Na Kong; Chan Feng; Ye Zhang; Mikyung Yu; Tian Xie; Zameer Bharwani; Bader M Aljaeid; Bingyang Shi; Wei Tao; Omid C Farokhzad
Journal:  ACS Nano       Date:  2018-12-04       Impact factor: 15.881

9.  Nanoparticle encapsulation of mitaplatin and the effect thereof on in vivo properties.

Authors:  Timothy C Johnstone; Nora Kulak; Eric M Pridgen; Omid C Farokhzad; Robert Langer; Stephen J Lippard
Journal:  ACS Nano       Date:  2013-05-22       Impact factor: 15.881

10.  Activation of Platinum(IV) Prodrugs By Motexafin Gadolinium as a Redox Mediator.

Authors:  Gregory Thiabaud; Rebecca McCall; Guangan He; Jonathan F Arambula; Zahid H Siddik; Jonathan L Sessler
Journal:  Angew Chem Int Ed Engl       Date:  2016-07-05       Impact factor: 15.336

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.